ALK B ALK-ABELLO A/S

Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025

Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025

ALK (ALKB.DC / OMX: ALK B) will publish its results for the first quarter of 2025 in the morning on Tuesday, 6 May 2025.

Later on the same day, the company will host a presentation for investors and analysts at 11:00 a.m. CEST, where ALK’s management will comment on the results and outlook and be available for questions.

ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR. 

Live audio webcast

The meeting will be audio webcasted live and be available for replay on .

Conference call

If you wish to participate via telephone, please register for the conference call by using this link: and follow the instructions. You will receive an email from with dial-in details, including a passcode and a pin code. Please make sure to whitelist  and/or check your spam filter. We advise you to register on the day before the call at the latest.

Presentation

The presentation will be available on shortly before the meeting starts.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. , mobile

Media: Maiken Riise Andersen, tel.

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at

Attachment



EN
29/04/2025

Underlying

ALK BALK-ABELLO A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-ABELLO A/S

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
12h / 58m 12h / 58m 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK indgår co-promotion-aftale vedrørende neffy® i USA

ALK indgår co-promotion-aftale vedrørende neffy® i USA Co-promotion-aftale med ARS Pharma baseret på omkostningsdeling og performance-baseret indtægtsdeling.ALK fremskynder opbygningen af selskabets pædiatriske salgskanal på en balanceret måde.  Aftalen påvirker ikke ALK's forventninger til omsætning og indtjening i 2025. ALK (ALKB.DC / OMX: ALK B) har i dag annonceret en fireårig aftale med amerikanske ARS Pharmaceuticals, Inc. (“ARS Pharma”, NASDAQ: SPRY) om markedsføring af neffy® (adrenalinnæsespray) til op mod 9.000 børnelæger i USA. Disse børnelæger står aktuelt for tæt på 10% af all...

May 2, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK enters into neffy® co-promotion agreement in the USA

ALK enters into neffy® co-promotion agreement in the USA Co-promotion with ARS Pharma based on cost sharing and performance-based revenue sharing.ALK to accelerate build-up of its US paediatric sales channel in a balanced way. Agreement does not change ALK’s revenue and earnings outlook for 2025. ALK (ALKB.DC / OMX: ALK B) today announced a 4-year agreement with US-based ARS Pharmaceuticals, Inc. (“ARS Pharma”, NASDAQ: SPRY) to co-promote the neffy® adrenaline (epinephrine) nasal spray to up to 9,000 named paediatricians in the USA. These paediatricians currently account for close to 10% o...

May 2, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Invitation til præsentation af ALK’s regnskab for første kvartal 2025 ...

Invitation til præsentation af ALK’s regnskab for første kvartal 2025 tirsdag den 6. maj 2025 ALK (ALKB.DC / OMX: ALK B) offentliggør delårsrapport for de første tre måneder af 2025 (Q1) om morgenen tirsdag den 6. maj 2025. ALK afholder senere samme dag kl. 11.00 (CEST) en præsentation for investorer og analytikere, hvor ledelsen kommenterer på resultat og forventninger samt besvarer spørgsmål. ALK vil være repræsenteret ved Peter Halling, Adm. direktør, Claus Steensen Sølje, Finansdirektør og Per Plotnikof, IR-chef.  Live audio-webcast Mødet audiocastes live på , hvor genafspilning a...

April 29, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Invitation to the presentation of ALK’s first quarter 2025 results on ...

Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025 ALK (ALKB.DC / OMX: ALK B) will publish its results for the first quarter of 2025 in the morning on Tuesday, 6 May 2025. Later on the same day, the company will host a presentation for investors and analysts at 11:00 a.m. CEST, where ALK’s management will comment on the results and outlook and be available for questions. ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR.  Live audio webcast The meeting will be audio web...

April 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch